Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Clin Microbiol Infect ; 21(10): 938-45, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26093076

ABSTRACT

Several studies have reported an increased incidence of candidaemia and a redistribution of species, with a decrease in the number of Candida albicans isolates. In Norway, a prospective, national surveillance study of candidaemia has been ongoing since 1991. Data from the period 1991-2003 have been published previously. The aim of this study was to follow up the incidence, species distribution and antifungal susceptibility of Candida species isolates from blood cultures in the period 2004-2012, and compare them with the corresponding findings from the period 1991-2003. Blood culture isolates of Candida species from all medical microbiological laboratories in Norway were identified and susceptibility tested at the Norwegian Mycological Reference Laboratory. A total of 1724 isolates were recovered from 1653 patients in the period 2004-2012. Comparison of the two periods showed that the average incidence of candidaemia episodes per 100 000 inhabitants increased from 2.4 (1991-2003) to 3.9 (2004-2012). The increase in incidence in the latter period was significantly higher in patients aged >40 years (p 0.001), and a marked increase was observed in patients aged >60 years (p < 0.001). In conclusion, the average incidence in Norway over a period of 22 years modestly increased from 2.4 to 3.9 per 100,000 inhabitants, this being mainly accounted for by candidaemia in the elderly. The species distribution was stable, and the rate of acquired resistance was low.


Subject(s)
Candida/classification , Candida/isolation & purification , Candidemia/epidemiology , Candidemia/microbiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Antifungal Agents/pharmacology , Candida/drug effects , Child , Child, Preschool , Drug Resistance, Fungal , Epidemiological Monitoring , Female , Humans , Incidence , Infant , Infant, Newborn , Male , Microbial Sensitivity Tests , Middle Aged , Norway/epidemiology , Prospective Studies , Young Adult
2.
Eur J Clin Microbiol Infect Dis ; 31(6): 1181-6, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21960034

ABSTRACT

Despite rapidly diminishing treatment options for Neisseria gonorrhoeae and high levels of ciprofloxacin resistance worldwide, Norwegian guidelines still recommend ciprofloxacin as empirical treatment for gonorrhea. The present study aimed to characterize phenotypical and genotypical properties of N. gonorrhoeae isolates in Norway in 2009. All viable N. gonorrhoeae isolates (n = 114) from six university hospitals in Norway (2009) were collected, representing 42% of all notified gonorrhea cases. Epidemiological data were collected from the Norwegian Surveillance System for Communicable Diseases and linked to phenotypical and genotypical characteristics for each N. gonorrhoeae isolate. Resistance levels to the antimicrobials examined were: ciprofloxacin 78%, azithromycin 11%, cefixime 3.5%, ceftriaxone 1.8%, and spectinomycin 0%. The minimum inhibitory concentrations of gentamicin varied from 1.5 to 8 mg/L. Forty-one (36%) of the isolates were ß-lactamase-producing, 17 displayed penA mosaic alleles, and 72 different N. gonorrhoeae multiantigen sequence types (ST; 37 novel) were identified. The most common ST was ST1407 (n = 11), containing penA mosaic allele. Four of these isolates displayed intermediate susceptibility/resistance to cefixime. The N. gonorrhoeae strains circulating in Norway were highly diverse. The level of ciprofloxacin resistance was high and the Norwegian management guidelines should promptly exclude ciprofloxacin as an empirical treatment option for gonorrhea.


Subject(s)
Drug Resistance, Bacterial , Gonorrhea/epidemiology , Gonorrhea/microbiology , Neisseria gonorrhoeae/isolation & purification , Adolescent , Adult , Anti-Bacterial Agents/pharmacology , Female , Genotype , Hospitals, University , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Molecular Typing , Neisseria gonorrhoeae/drug effects , Neisseria gonorrhoeae/genetics , Norway/epidemiology , Practice Guidelines as Topic , Young Adult
3.
Tidsskr Nor Laegeforen ; 118(26): 4070-3, 1998 Oct 30.
Article in Norwegian | MEDLINE | ID: mdl-9844510

ABSTRACT

During the last decade antimicrobial resistant pathogens have become a major medical problem. Internationally, multiresistant enterococci have increased nosocomial morbidity and mortality. Such strains are often resistant to ampicillin, aminoglycosides, and glycopeptides such as vancomycin. The spread of these strains has been shown to correlate to the use of antibiotics and the practice of suboptimal infection control within health care facilities. The current situation in Norwegian hospitals is presented, including the only six cases with infections and the three carriers of vancomycin resistant enterococci found to date. Surveillance in the hospitals shows that such strains are uncommon in non-infected patients. To maintain this favourable situation it is necessary to continue to practice effective methods of infection control and to employ sound antibiotic policies.


Subject(s)
Cross Infection/drug therapy , Drug Resistance, Multiple , Enterococcus/drug effects , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Communicable Disease Control , Cross Infection/epidemiology , Cross Infection/immunology , Enterococcus/classification , Enterococcus/immunology , Humans , Infection Control , Norway/epidemiology , Vancomycin/administration & dosage , Vancomycin/adverse effects
4.
Tidsskr Nor Laegeforen ; 118(8): 1188-90, 1998 Mar 20.
Article in Norwegian | MEDLINE | ID: mdl-9567694

ABSTRACT

Enterococci are part of the normal human and animal bowel flora. They are considered bacteria of relatively low virulence, but are important nosocomial pathogens. In the context of their intrinsic resistance to a number of antimicrobial agents, the rapid emergence of multiresistant enterococci is alarming. As inhabitants of the gastrointestinal tract, they come into close contact with other bacteria and may pass antibiotic resistance genes to them. We report the first case of infection with a VanA vancomycin-resistant. Enterococcus in Norway. The strain was identified as Enterococcus faccium with high level resistance to aminoglycosides, ampicillin, teicoplanin and vancomycin. The VanA phenotype was confirmed by PCR detection of the vanA gene. Transmission, treatment, prevention, and control of infections with vancomycin-resistant enterococci is discussed.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Enterococcus faecium/drug effects , Gram-Positive Bacterial Infections/drug therapy , Vancomycin/therapeutic use , Aged , Drug Resistance, Microbial , Enterococcus faecium/genetics , Enterococcus faecium/immunology , Female , Gram-Positive Bacterial Infections/immunology , Gram-Positive Bacterial Infections/transmission , Humans , Phenotype
SELECTION OF CITATIONS
SEARCH DETAIL
...